All News

Top news of the day from across the health care landscape.

Two phase 3 studies evaluating the triple combination regimen met the primary endpoint of improvement in lung function in patients with at least 1 F508del mutation.

Top news of the day from across the health care landscape.

Health care providers managing patients with MS should remain cognizant of the link between unhealthy lifestyle behaviors and depression risks.

Bodily fluids may serve as vectors for transmission for transmitting hepatitis C virus RNA in patients with a high viral load.

High-dose intravitreal triamcinolone acetonide deemed a safe and low-cost alternative to anti-vascular endothelial growth factor agents for diabetic macular edema.

Hot flashes are a huge problem across the general population, but even more so in breast cancer survivors.

In related news, manufacturer of palonosetron hydrochloride was recently awarded the Drug Shortage Assistance Award from the US FDA,

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Immunotherapy checkpoint inhibitors have changed the landscape of oncology treatment, however, they can come with a risk of adverse effects and, in rare cases, cause serious medical problems.

Atezolizumab (Tecentriq) approved by FDA in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of metastatic nonsquamous non-small cell lung cancer.

Top news of the week from Specialty Pharmacy Times.

Specialty pharmacies offer a wide range of services vital to manufacturers and patients alike.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Onasemnogene abeparvovec (Zolgensma) is a 1-time infusion that replaces the defective or missing SMN1 gene with a functional copy.

HIV is not associated with preterm delivery, though antiretroviral therapy is, but hepatitis C may be a potential risk factor.

We know that burnout continues to plague health care professionals.

An analysis indicates that immune-related adverse events may be more common than initially reported in the clinical trials for these therapies.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Combination of azacitidine and nivolumab shows efficacy in patients with an average of 2 prior treatments for relapsed or refractory AML.

Detecting hepatitis C RNA in peripheral blood mononuclear cells or liver cells in patients who are negative for viral RNA raises questions about the risk of transmission to other individuals.

Just under one-fourth of all Americans have arthritis.

Are your business decisions putting money into your bank account?

These products are being recalled due to detected trace amounts of an impurity, N-nitrosodiethylamine (NDEA) contained in the API valsartan.